摘要
目的观察不同降脂治疗方案对糖耐量异常合并高脂血症的疗效及安全性。方法将168例糖耐量异常合并高脂血症的患者随机分为三组,即血脂康组,辛伐他汀组和生活方式干预组(对照组),治疗8个月后观察疗效。结果血脂康组及辛伐他汀组治疗8个月后TC、TG、LDL-C水平与治疗前对比有显著性降低,HDL-C显著升高(P<0.01),而对照组Tch、TG、LDL-C治疗后水平仅有轻度降低,HDL-C轻度升高(P>0.05)。血脂康组FBS、2hPG及HbAIc与治疗前相比也有明显降低(P<0.05);辛伐他汀组和对照组FBS、2hPG及HbAIc与治疗前相比降低不明显(P>0.05)。结论血脂康更适合糖耐量异常合并高脂血症患者,能有效降低高脂血症及改善糖耐量异常,且安全性良好,值得在临床推广。
Objective The study was conducted to investigate the clinical efficacy and safety of different ways of lipid-modulating treatment for patients with impaired glucose tolerance and hyperlipemia. Methods 168 cases of patients with impaired glucose tolerance and hyperlipemia were randomly allocated to xuezhikang group, simvastatin group and lifestyle intervention group respectively, the therapeutic results were tested 8 months after treatment. Results After 8 months treatment, the lipid profile was evidently improved in xuezhikang group and simvastatin group. level of total cholesterol （ TC ）, triglyeeridemia （ TG ）, low-density lipoprotein cholesterol （ LDL-C ） were significantly reduced and high-density lipoprotein cholesterol （ HDL-C ） increased significantly （P〈0.01）. Slightly change of above indicators were found in control group （P〉0.05）. The level of fasting plasma glucose （ FBS ）, 2 hours plasma glucose （ 2 hPG ） and glycohemoglobin （ HbAIc ） decreased obviously in xuezhikang group （P〈0.05）, while there were no obviously change of above-mentioned indices in both simvastatin group and lifestyle intervention group （P〉0.05）. Conclusion These results indicated that xuezhikang is effective in reducing hyperlipemia, improving impaired glucose tolerance, and it is safe. Therefore, xuezhikang is much more suitable for the treatment of patients with impaired glucose tolerance and hyperlipemia, it is worth to be widely used clinically.
出处
《当代医学》
2013年第20期2-4,共3页
Contemporary Medicine
关键词
降脂治疗
糖耐量异常
高脂血症
Lipid-regulating
treatment Impaired glucose tolerance
Hyperlipemia
